VPA10387/059/003

Rimadyl Palatable Tablets 100 mg

Variation	Summary	Date
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	07/07/23
B.II.e.1.a.1	IA - B.II.e.1.a.1 - 1. Solid pharmaceutical forms - B.II.e.1.a.1 - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	08/02/22
B.II.e.1.a.1	IA - B.II.e.1.a.1 - 1. Solid pharmaceutical forms - B.II.e.1.a.1 - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	08/02/22
B.II.e.4.a	IA - B.II.e.4.a - a) Non-sterile medicinal products - B.II.e.4.a - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	08/02/22